| |
|
|
Combination of a transient assay based ChIP technology and transcriptome analyses for the exploration of potential transcription factor binding sites
Institute of Plant and Microbial Biology, Academia Sinica
1. Combination of protoplast transient expression system and Nickel resin based purification is an useful approach for chromatin enrichment that can be used to identify transcription factor’s potential target genes. 2.Comparison our ChIP-on-chip target genes with in vivo binding targets using two whole genome tiling array platforms showing high degree of overlap between two methods.
|
A high-throughput protein array-based approach
Centre for Proteomic and Genomic Research
Here we present a novel discovery-oriented high-throughput approach to the screening of allergen reactivates in crude biological extracts is presented using seafood allergens as an example. The CPGR workflow permits the effective screening of hundreds of putative allergens in parallel using minute amounts of patient serum and constitutes a cost-efficient allergen-specific antibody screening method for a routine diagnostic setting.
|
Apoptosis Inducing Novel microRNA for Breast cancer and Hepatocellular Carcinoma
UC Davis Medical Center
MicroRNA provides a mechanism to target cancer stem cells and restraint tumors cells permanently; this could lead to promising cancer therapeutics and imaging agents. Apoptosis inducing microRNA was identified to target HCC and breast cancer cells for imaging and therapy.
|
|
|
|
|
|
Regulatory Services Business Development
Recruiter: VRS Regulatory
Central Scotland, UK
|
|
|
Team Leader, Bioanalysis
Biodynamics Research Limited
Rushden, Northants, UK
|
|
|
Regulatory Toxicologist
VRS Regulatory
Cheshire, UK
|
|
|
Metabonomics Scientist
Nestlé Research Center
Lausanne, Switzerland
|
|
|
NanoBio Commercialisation Manager
Cenamps
Newcastle Upon Tyne, UK
|
|
|
Laboratory Technician
Peptide Protein Research
UK
|
|
|
Direct Sales - LCMS Product Specialist
Agilent Technologies
Multiple US Regions
|
|
|
Account Manager
Evolution Life Science
West Midlands, UK
|
|
|
Project Manager
Evolution Life Science
South East, UK
|
|
|
Sales Specialist
Evolution Life Science
Cambridge/East Midlands, UK
|
|
|
|
XX International Congress of Genetics, Berlin, Germany
12 July 2008 - 17 July 2008
The International Congress of Genetics, organized under the auspices of the International Genetics Federation.
The program and additional important information can also be obtained upon visiting the congress web page: www.geneticsberlin2008.com.
|
IBC’s 3rd Annual Beyond Antibodies, La Jolla, CA, USA
28 July 2008 - 29 July 2008
IBC’s 3rd Annual Beyond Antibodies conference on July 28-29, 2008 in La Jolla, CA will discuss recent scientific as well as business developments antibody alternatives. Attend and review data from companies with antibody alternatives in clinical and preclinical stages.
|
Drug Discovery & Development of Innovative Therapeutics, Boston, MA, USA
04 August 2008 - 07 August 2008
Practical, Actionable Ideas for Accelerating Discovery and Early Development. The Drug Discovery & Development of Innovative Therapeutics (DDT) World Congress is the ONLY international event that compares applications of translational medicine and transforming technologies across multiple therapeutic areas to help you find new ways to achieve POC quickly. View the full program agenda online at www.drugdisc.com.
|
|
|
|
|
|
|
MicroRNA 2008
Published January 2008
This report presents an exhaustive analysis of all the products and services offered by the various vendors into the microRNA market. Select Biosciences' proprietary market surveys addressed the qualitative and quantitative trends in the microRNA research market in terms of challenges, opportunities, and quantitative industry metrics—all the raw data and analyses based on the data are presented. In addition to the microRNA research market, this report also addresses the industry dynamics/trends
|
Personalized Medicine Market Report 2007
Published April 2007
This report presents the latest industry analysis of the emerging field of Personalized Medicine. There is increasing interest in this field driven by the development of a number of molecular diagnostics-based tests that determine a patient’s genetic predisposition to a given disease—such as cancer, or to adverse drug reactions (ADRs).
|
|